Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cash & Equivalents	474.34	391.57	549.91	285.12	262.13	69.88
Short-Term Investments	-	-	-	231.45	-	-
Cash & Short-Term Investments	474.34	391.57	549.91	516.56	262.13	69.88
Cash Growth	16.87%	-28.79%	6.46%	97.07%	275.09%	-
Accounts Receivable	-	-	-	0.03	0.16	0.15
Other Receivables	2.53	3.09	2.75	9.06	-	-
Receivables	2.53	3.09	2.75	9.09	0.16	0.15
Restricted Cash	1.78	3.23	1.28	1.55	2	5.29
Other Current Assets	43.73	40.25	15.87	7.51	2.16	1.08
Total Current Assets	522.38	438.14	569.81	534.72	266.44	76.4
Property, Plant & Equipment	156.28	120.17	121.45	64.73	25.97	24.37
Goodwill	52.06	52.06	0.8	0.8	0.8	-
Other Intangible Assets	38.21	36.44	1.31	1.39	1.69	-
Other Long-Term Assets	6.94	6.89	7.92	8.72	3.69	0.07
Total Assets	775.86	653.7	701.29	610.35	298.59	101.43
Accounts Payable	3.76	3.95	4.59	2.82	1.07	1.26
Accrued Expenses	31.48	41.76	30.29	27.67	10.49	4.88
Current Portion of Long-Term Debt	1.11	0.04	0.1	0.09	1.07	0.08
Current Portion of Leases	15.61	6.12	5.95	-	-	-
Current Unearned Revenue	32.2	36.43	56.73	10	10	-
Other Current Liabilities	1.92	4.87	2.62	6.08	0.47	0.47
Total Current Liabilities	86.08	93.17	100.27	46.66	23.1	6.68
Long-Term Debt	-	1.1	0.54	0.63	11.41	12.42
Long-Term Leases	73.16	43.41	44.42	-	-	-
Long-Term Unearned Revenue	29.17	51.24	70.26	6.67	16.67	-
Long-Term Deferred Tax Liabilities	-	1.34	-	-	-	-
Other Long-Term Liabilities	3	-	-	13.45	5.38	5.49
Total Liabilities	191.41	190.26	215.48	67.41	56.56	24.59
Common Stock	0	0	0	0	-	-
Additional Paid-In Capital	1,741	1,431	1,125	943.14	7.31	2.33
Retained Earnings	-1,157	-967.62	-639.56	-400.08	-213.6	-126.6
Comprehensive Income & Other	-	-	-	-0.13	-	-
Total Common Equity	584.45	463.44	485.81	542.94	-206.29	-124.27
Shareholders' Equity	584.45	463.44	485.81	542.94	242.02	76.84
Total Liabilities & Equity	775.86	653.7	701.29	610.35	298.59	101.43
Total Debt	89.88	50.67	51.01	0.72	12.49	12.5
Net Cash (Debt)	384.47	340.89	498.91	515.84	249.64	57.39
Net Cash Growth	8.92%	-31.67%	-3.28%	106.63%	335.00%	-
Net Cash Per Share	1.69	1.64	2.84	4.12	11.46	2.66
Filing Date Shares Outstanding	280.97	234.65	191.23	170.77	22.31	21.64
Total Common Shares Outstanding	280.97	234.27	191.02	170.27	22.31	21.64
Working Capital	436.29	344.97	469.55	488.06	243.34	69.71
Book Value Per Share	2.08	1.98	2.54	3.19	-9.24	-5.74
Tangible Book Value	494.18	374.94	483.7	540.75	-208.78	-124.27
Tangible Book Value Per Share	1.76	1.60	2.53	3.18	-9.36	-5.74
Machinery	86.51	82.22	67.69	53.08	20.78	17.19
Construction In Progress	2.8	3.23	8.75	16.45	1.36	-
Leasehold Improvements	46.78	45.93	41.87	13.94	13.79	12.9

Source: S&P Capital IQ. Standard template. Financial Sources.